Mairs and Power's PFE Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 73,921 shares of Pfizer Inc. (PFE) worth $1.84 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2015, adding 833,414 shares. Largest reduction occurred in Q4 2021, reducing 884,335 shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Mairs and Power
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1,423 | Reduce 1.89% | 73,921 | $24.90 |
| Q3 2025 | -2,115 | Reduce 2.73% | 75,344 | $25.48 |
| Q2 2025 | +3,870 | Add 5.26% | 77,459 | $24.24 |
| Q1 2025 | -5,713 | Reduce 7.20% | 73,589 | $25.34 |
| Q4 2024 | -23,900 | Reduce 23.16% | 79,302 | $26.53 |
| Q3 2024 | -8,533 | Reduce 7.64% | 103,202 | $28.94 |
| Q2 2024 | -23,655 | Reduce 17.47% | 111,735 | $27.98 |
| Q1 2024 | -39,586 | Reduce 22.62% | 135,390 | $27.75 |
| Q4 2023 | -82,576 | Reduce 32.06% | 174,976 | $28.79 |
| Q3 2023 | -67,630 | Reduce 20.80% | 257,552 | $33.17 |
| Q2 2023 | -45,648 | Reduce 12.31% | 325,182 | $36.68 |
| Q1 2023 | -71,985 | Reduce 16.26% | 370,830 | $40.80 |
| Q4 2022 | -28,278 | Reduce 6.00% | 442,815 | $51.24 |
| Q3 2022 | -34,395 | Reduce 6.80% | 471,093 | $43.76 |
| Q2 2022 | -94,764 | Reduce 15.79% | 505,488 | $52.43 |
| Q1 2022 | -151,046 | Reduce 20.10% | 600,252 | $51.77 |
| Q4 2021 | -884,335 | Reduce 54.07% | 751,298 | $59.05 |
| Q3 2021 | -324,048 | Reduce 16.54% | 1.64 M | $43.01 |
| Q2 2021 | -50,736 | Reduce 2.52% | 1.96 M | $39.16 |
| Q1 2021 | -61,137 | Reduce 2.95% | 2.01 M | $36.23 |
| Q4 2020 | -197,088 | Reduce 8.69% | 2.07 M | $36.81 |
| Q3 2020 | -251,279 | Reduce 9.97% | 2.27 M | $36.70 |
| Q2 2020 | -233,610 | Reduce 8.48% | 2.52 M | $32.70 |
| Q1 2020 | -61,883 | Reduce 2.20% | 2.75 M | $32.64 |
| Q4 2019 | -1,228 | Reduce 0.04% | 2.82 M | $39.18 |
| Q3 2019 | +447 | Add 0.02% | 2.82 M | $35.93 |
| Q2 2019 | -11,315 | Reduce 0.40% | 2.82 M | $43.32 |
| Q1 2019 | -71,998 | Reduce 2.48% | 2.83 M | $42.47 |
| Q4 2018 | -573,950 | Reduce 16.52% | 2.9 M | $43.65 |
| Q3 2018 | -498,270 | Reduce 12.55% | 3.47 M | $44.07 |
| Q2 2018 | -255,342 | Reduce 6.04% | 3.97 M | $36.28 |
| Q1 2018 | -490,258 | Reduce 10.39% | 4.23 M | $35.49 |
| Q4 2017 | -49,443 | Reduce 1.04% | 4.72 M | $36.22 |
| Q3 2017 | -102,056 | Reduce 2.10% | 4.77 M | $35.70 |
| Q2 2017 | -2,280 | Reduce 0.05% | 4.87 M | $33.59 |
| Q1 2017 | +145,929 | Add 3.09% | 4.87 M | $34.21 |
| Q4 2016 | +170,105 | Add 3.73% | 4.73 M | $32.48 |
| Q3 2016 | +72,785 | Add 1.62% | 4.56 M | $33.87 |
| Q2 2016 | +79,745 | Add 1.81% | 4.48 M | $35.21 |
| Q1 2016 | +505,214 | Add 12.96% | 4.4 M | $29.64 |
| Q4 2015 | +833,414 | Add 27.20% | 3.9 M | $32.28 |
| Q3 2015 | +712,432 | Add 30.30% | 3.06 M | $31.41 |
| Q2 2015 | -12,023 | Reduce 0.51% | 2.35 M | $33.53 |
| Q1 2015 | -294,095 | Reduce 11.07% | 2.36 M | $34.79 |
| Q4 2014 | +27,584 | Add 1.05% | 2.66 M | $31.15 |
| Q3 2014 | +56,721 | Add 2.20% | 2.63 M | $29.57 |
| Q2 2014 | +11,992 | Add 0.47% | 2.57 M | $29.68 |
| Q1 2014 | -8,801 | Reduce 0.34% | 2.56 M | $32.12 |
| Q4 2013 | -14,715 | Reduce 0.57% | 2.57 M | $30.63 |
| Q3 2013 | -35,153 | Reduce 1.34% | 2.58 M | $28.73 |
| Q2 2013 | +2.62 M | Add 0.00% | 2.62 M | $28.01 |
Mairs and Power's Pfizer Investment FAQs
Mairs and Power first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 2,619,973 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held Pfizer Inc. (PFE) for 51 quarters since Q2 2013.
Mairs and Power's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 2,619,973 shares worth $73.38 M.
According to the latest 13F filing for Q4 2025, Mairs and Power's firm, Mairs & Power INC, owns 73,921 shares of Pfizer Inc. (PFE), valued at approximately $1.84 M.
As of the Q4 2025 filing, Pfizer Inc. (PFE) represents approximately 0.02% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings.
Mairs and Power's peak holding in Pfizer Inc. (PFE) was 4,871,107 shares, as reported at the end of Q1 2017.